Clinical Trial: Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Renal Cell Carcinoma
Study Type: INTERVENTIONAL
Official Title: Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
Brief Summary:
The goal of this Clinical Study is to understand the outcomes by informing therapy choice for adjuvant treatment in clear cell renal cell carcinoma by using molecular residual disease.The main question[s] it aims to answer are:what is the progression free survival of a cohort of high risk resected RCC patients when treated based on MRDwhat is the overall survival of high risk resected RCC patients when treated based on MRDParticipants will forgo adjuvant therapy with pembrolizumab if they have no detectable…
Read more